Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Forecast & Price Target
Contineum Therapeutics, Inc. Class A Common Stock · NASDAQ
$13.84-0.23 (-1.60%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Contineum Therapeutics, Inc. Class A Common Stock, 3 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $16.00 to $22.00, so the covering firms are broadly aligned. The average target of $19.50 sits 41% above the current $13.84. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.43 next quarter toward $-1.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy375%
Hold125%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Contineum Therapeutics, Inc. Class A Common Stock.
As of Jul, 3 of 4 firms rate CTNM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CTNM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.43
Range $-0.52 – $-0.22 · 7 analysts · -5% YoY
Next period, 7 analysts expect Contineum Therapeutics, Inc. Class A Common Stock to earn $-0.43 a share (range $-0.52 – $-0.22), versus $-0.45 a year earlier. Full-year consensus is $-1.65, growing to $-1.81 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $11.0M next year.
Top analysts covering Contineum Therapeutics, Inc. Class A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTNM.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Hold
$16.00+15.6% to target
Overall win rate
61%
+ Follow
#2
Joel Beatty
Baird · Rank #111
Buy
$20.00+44.6% to target
Overall win rate
46%
+ Follow
#3
Brian Abrahams
RBC Capital · Rank #311
Buy
$22.00+59.0% to target
Overall win rate
25%
+ Follow
#4
CM
Charles Moore
Robert W. Baird
Buy
$20.00+44.6% to target
Coverage
—
+ Follow
#5
Faisal Khurshid
Jefferies
Buy
$21.00+51.8% to target
Coverage
—
+ Follow
CTNM stock forecast FAQ
What is CTNM's average 12-month price target?+
The 4 analysts with a live target average $19.50 for Contineum Therapeutics, Inc. Class A Common Stock over the next 12 months, ranging from a $22.00 high to a $16.00 low.
Is CTNM stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CTNM?+
The Street-high target is $22.00 (RBC Capital), and the Street-low is $16.00 (Morgan Stanley). The average of all 4 active targets is $19.50.
How many Wall Street analysts cover CTNM?+
4 analysts have an active rating on Contineum Therapeutics, Inc. Class A Common Stock, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering CTNM?+
Among analysts who currently cover CTNM, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Hold with a $16.00 target.
What is Contineum Therapeutics, Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.43 per share (range $-0.52 – $-0.22) across 7 analysts. Full-year EPS is projected at $-1.65, rising to $-1.81 the following year.
How much revenue is Contineum Therapeutics, Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $11.0M next year.
Have analysts been upgrading or downgrading CTNM lately?+
As of Jul, 3 of 4 firms rate CTNM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTNM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
